Ecologically Valid, Ambient, Longitudinal, and Unbiased Assessment of Treatment Efficacy in Parkinson’s Disease (EVALUATE-PD)
Objective: To determine the feasibility of using in-home digital biomarkers (DBs) and activity monitoring for clinical trials and studies of early Parkinson’s Disease (PD) and…A Phase 1b Study to Investigate Safety and Tolerability of Repeated Subcutaneous Doses of HER-096 in Subjects with Parkinson’s Disease
Objective: To investigate safety and tolerability of repeated subcutaneous (s.c.) doses of HER-096 in subjects with Parkinson’s disease. Background: HER-096 is a retro-inverso isomerized peptide…ATH434 Slowed Disease Progression in a Phase 2 Study in Multiple System Atrophy
Objective: Evaluate the efficacy and safety of ATH434 treatment in individuals with MSA Background: Multiple system atrophy (MSA) is a rapidly progressive neurodegenerative disorder without…A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the NLRP3 Inhibitor Vent-02 in Patients with Mild to Moderate Parkinson’s Disease
Objective: To describe the innovative Phase 2 study design aimed to investigate vent-02 in the treatment of PD. Background: NLRP3 hyperactivation plays a critical role…Bidirectional Relationships Between Frailty and DNAm Age Acceleration and its Mediation Effects on Physical Disability and Mortality
Objective: This study aims to investigate the bidirectional associations between frailty and DNA methylation (DNAm) age acceleration (AgeAccel), and further test whether epigenetic aging mediates…PADOVA: Topline results from a Phase IIb study of prasinezumab in early-stage Parkinson’s disease participants on stable symptomatic treatment
Objective: To evaluate the effect of prasinezumab on slowing down disease progression in participants with early-stage Parkinson’s disease (PD) on stable symptomatic medication. Background: Prasinezumab…Neuroprotective Role of Diosgenin-Loaded Lipid Nanoparticles for Parkinson’s Disease: Pharmacokinetic and Pharmacodynamic Insights
Objective: To develop, optimize, and evaluate diosgenin-loaded solid lipid nanoparticles (DG-SLNs) and nanostructured lipid carriers (DG-NLCs) incorporated into hydrogel formulations (DG-SLN-C and DG-NLC-C) for improved…Peripheral insulin resistance may predict exenatide treatment response in Parkinson’s disease
Objective: To explore if the glucagon-like peptide-1 (GLP-1) receptor agonist, exenatide could modify the course of Parkinson’s disease (PD) and if peripheral insulin resistance (IR) mightdifferentially impact on this. Background: Exenatide…Therapeutic Efficacy of Human Dental Pulp Stem Cells-Derived Exosome-Encased Phloroglucinol In MPTP-Induced Chronic Parkinsonian Rat model: Potential for Disease Modification
Objective: This study aimed to evaluate the therapeutic efficacy of intranasally administered exosome-encased phloroglucinol (Exo-Phl) in a MPTP rat model of PD. Background: Dopaminergic (DA)…Cognitive and Motor Wobbling in Isolated RBD: A Multicentric Study by the International RBD Study Group (IRBDSG)
Objective: To define and characterize clinically fluctuating transition phases from isolated RBD (iRBD) to overt alpha-synucleinopathy. Background: Patients with iRBD often develop motor and non-motor…
- 1
- 2
- 3
- …
- 19
- Next Page »